药物涂层球囊在血液透析通路中的应用进展

doi:10.3969/j.issn.1671-4091.2022.04.014

摘要/Abstract

摘要： 【摘要】血液透析通路是尿毒症患者的生命线，通路的并发症严重影响着患者的生存寿命。介入下经皮腔内球囊扩张血管成形术是解决通路狭窄、血栓的重要方法，由于其微创、保留了原有通路、不影响透析等特点，近年来被推广于临床，但因其价格相对较高，其社会经济性及并发症情况仍是多数医生及患者考量的重要内容。本文将针对药物涂层球囊在血液透析通路的应用进展进行综述。

关键词: 血液透析通路, 经皮球囊扩张血管成形治疗, 药物涂层球囊

Abstract: 【Abstract】Hemodialysis access is a lifeline for end stage renal disease patients. The complications in the access route endanger the patient’s life. Percutaneous transluminal balloon angioplasty is an important manipulation useful for the treatment of arteriove-nous fistula stenosis and thrombosis, which is widely used clinically due to its minimal trauma, repairment of the original route and recovery of is function immediately after the manipulation. However, because of the higher expense of this manipulation, its cost-effectiveness and complications are often concerned by the doctors and patients. This article reviews the recent progresses in the application of drug-coated balloons for hemodialysis access.

Key words: Hemodialysis access, Percutaneous transluminal angioplasty, Drug-coated balloon

中图分类号:

R318.16

李云峰, 郭红霞, 史振伟. 药物涂层球囊在血液透析通路中的应用进展[J]. 中国血液净化, 2022, 21(04): 284-287.

参考文献

[1] Saran R, Robinson B, Abbott K. United States Renal Data System: 2016 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States [J]. American Journal of Kidney Diseases, 2017, 69(3): A4.
[2] Chatzimanouil M K T, Wilkens L, Anders H J. Quantity and Reporting Quality of Kidney Research [J]. J Am Soc Nephrol, 2019, 30(1): 13-22.
[3] Lok C E, Huber T S, Lee T, Shenoy S, Yevzlin A S, Abreo K, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update [J]. Am J Kidney Dis, 2020, 75(4 Suppl 2): S1-s164.
[4] 金其庄, 王玉柱, 叶朝阳, 施雅雪. 中国血液透析用血管通路专家共识(第2版) [J]. 中国血液净化, 2019, 18(06): 365-81.
[5] Viecelli A K, Mori T A, Roy-Chaudhury P, Polkinghorne K R, Hawley C M, Johnson D W, et al. The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled [J]. Semin Dial, 2018, 31(3): 244-57.
[6] Riella M C, Roy-Chaudhury P. Vascular access in haemodialysis: strengthening the Achilles' heel [J]. Nat Rev Nephrol, 2013, 9(6): 348-57.
[7] Roy-Chaudhury P, Wang Y, Krishnamoorthy M, Zhang J, Banerjee R, Munda R, et al. Cellular phenotypes in human stenotic lesions from haemodialysis vascular access [J]. Nephrol Dial Transplant, 2009, 24(9): 2786-91.
[8] Cheung A K, Imrey P B, Alpers C E, Robbin M L, Radeva M, Larive B, et al. Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study [J]. J Am Soc Nephrol, 2017, 28(10): 3005-13.
[9] Allon M, Robbin M L. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions [J]. Kidney Int, 2002, 62(4): 1109-24.
[10] Roy-Chaudhury P, Kruska L. Future directions for vascular access for hemodialysis [J]. Semin Dial, 2015, 28(2): 107-13.
[11] Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO [J]. Arterioscler Thromb Vasc Biol, 2000, 20(12): E120-6.
[12] Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces [J]. J Intern Med, 2006, 259(4): 381-92.
[13] Roy-Chaudhury P, Sukhatme V P, Cheung A K. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint [J]. J Am Soc Nephrol, 2006, 17(4): 1112-27.
[14] Paszkowiak J J, Dardik A. Arterial wall shear stress: observations from the bench to the bedside [J]. Vasc Endovascular Surg, 2003, 37(1): 47-57.
[15] Smith G E, Gohil R, Chetter I C. Factors affecting the patency of arteriovenous fistulas for dialysis access [J]. J Vasc Surg, 2012, 55(3): 849-55.
[16] Miller C D, Robbin M L, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients [J]. J Am Soc Nephrol, 2003, 14(11): 2942-7.
[17] Miller P E, Carlton D, Deierhoi M H, Redden D T, Allon M. Natural history of arteriovenous grafts in hemodialysis patients [J]. Am J Kidney Dis, 2000, 36(1): 68-74.
[18] Wilson L, Miller H P, Farrell K W, Snyder K B, Thompson W C, Purich D L. Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends [J]. Biochemistry, 1985, 24(19): 5254-62.
[19] Jordan M A, Toso R J, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations [J]. Proc Natl Acad Sci U S A, 1993, 90(20): 9552-6.
[20] Wessely R, Sch?mig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different [J]. J Am Coll Cardiol, 2006, 47(4): 708-14.
[21] Katsanos K, Spiliopoulos S, Karunanithy N, Krokidis M, Sabharwal T, Taylor P. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery [J]. J Vasc Surg, 2014, 59(4): 1123-33.e8.
[22] Katsanos K, Karnabatidis D, Kitrou P, Spiliopoulos S, Christeas N, Siablis D. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial [J]. J Endovasc Ther, 2012, 19(2): 263-72.
[23] Kitrou P M, Katsanos K, Spiliopoulos S, Karnabatidis D, Siablis D. Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472) [J]. Eur J Radiol, 2015, 84(3): 418-23.
[24] Irani F G, Teo T K B, Tay K H, Yin W H, Win H H, Gogna A, et al. Hemodialysis Arteriovenous Fistula and Graft Stenoses: Randomized Trial Comparing Drug-eluting Balloon Angioplasty with Conventional Angioplasty [J]. Radiology, 2018, 289(1): 238-47.
[25] Liao M T, Lee C P, Lin T T, Jong C B, Chen T Y, Lin L, et al. A randomized controlled trial of drug-coated balloon angioplasty in venous anastomotic stenosis of dialysis arteriovenous grafts [J]. J Vasc Surg, 2020, 71(6): 1994-2003.
[26] Moreno-Sánchez T, Moreno-Ramírez M, Machancoses F H, Pardo-Moreno P, Navarro-Vergara P F, García-Revillo J. Efficacy of Paclitaxel Balloon for Hemodialysis Stenosis Fistulae After One Year Compared to High-Pressure Balloons: A Controlled, Multicenter, Randomized Trial [J]. Cardiovasc Intervent Radiol, 2020, 43(3): 382-90.
[27] Pang S Y C, Au-Yeung K C L, Liu G Y L, Tse R O H, Lai D, Leung W K W, et al. Randomized Controlled Trial for Paclitaxel-coated Balloon versus Plain Balloon Angioplasty in Dysfunctional Hemodialysis Vascular Access: 12-month Outcome from a Nonsponsored Trial [J]. Ann Vasc Surg, 2020,
[28] Lookstein R A, Haruguchi H, Ouriel K, Weinberg I, Lei L, Cihlar S, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas [J]. N Engl J Med, 2020, 383(8): 733-42.
[29] Kitrou P M, Papadimatos P, Spiliopoulos S, Katsanos K, Christeas N, Brountzos E, et al. Paclitaxel-Coated Balloons for the Treatment of Symptomatic Central Venous Stenosis in Dialysis Access: Results from a Randomized Controlled Trial [J]. J Vasc Interv Radiol, 2017, 28(6): 811-7.
[30] Trerotola S O, Roy-Chaudhury P, Saad T F. Drug-Coated Balloons in Dysfunctional Arteriovenous Fistulas: Is it Time? [J]. Am J Kidney Dis, 2020,
[31] Yin Y, Shi Y, Cui T, Li H, Chen J, Zhang L, et al. Efficacy and safety of paclitaxel-coated balloon angioplasty for dysfunctional arteriovenous fistulas: a multicenter randomized controlled trial [J]. Am J Kidney Dis, 2021,
[32] Kim J W, Kim J H, Byun S S, Kang J M, Shin J H. Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial [J]. Korean J Radiol, 2020, 21(11): 1239-47.
[33] Trerotola S O, Saad T F, Roy-Chaudhury P. The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis [J]. J Vasc Interv Radiol, 2020, 31(1): 1-14.e5.
[34] Therasse E, Caty V, Gilbert P, Giroux M F, Perreault P, Bouchard L, et al. Safety and Efficacy of Paclitaxel-Eluting Balloon Angioplasty for Dysfunctional Hemodialysis Access: A randomized trial Comparing with Angioplasty Alone [J]. J Vasc Interv Radiol, 2021,
[35] Kitrou P M, Spiliopoulos S, Katsanos K, Papachristou E, Siablis D, Karnabatidis D. Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial [J]. J Vasc Interv Radiol, 2015, 26(3): 348-54.
[36] Swinnen J J, Hitos K, Kairaitis L, Gruenewald S, Larcos G, Farlow D, et al. Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses [J]. J Vasc Access, 2019, 20(3): 260-9.
[37] Bj?rkman P, Weselius E M, Alb?ck A, Venermo M. Drug-Coated Balloons vs. Balloon Angioplasty in AV-Fistulas: A Randomized, Controlled Study with 1-Year Follow-Up [J]. European Journal of Vascular and Endovascular Surgery, 2019, 58(6): e93-e4.
[38] Maleux G, Vander Mijnsbrugge W, Henroteaux D, Laenen A, Cornelissen S, Claes K, et al. Multicenter, Randomized Trial of Conventional Balloon Angioplasty versus Paclitaxel-Coated Balloon Angioplasty for the Treatment of Dysfunctioning Autologous Dialysis Fistulae [J]. J Vasc Interv Radiol, 2018, 29(4): 470-5.e3.
[39] Gray R J, Sacks D, Martin L G, Trerotola S O. Reporting standards for percutaneous interventions in dialysis access [J]. J Vasc Interv Radiol, 2003, 14(9 Pt 2): S433-42.
[40] Kitrou P, Spiliopoulos S, Papadimatos P, Lampropoulos G, Christeas N, Karnabatidis D. Paclitaxel-coated balloon versus plain balloon angioplasty for the treatment of symptomatic central venous stenosis in dialysis access. Six-month results from a prospective single-center randomized trial [J]. Journal of Vascular and Interventional Radiology, 2016, 27(3): S161-S2.
[41] 赵德龙. 维持性血液透析患者流行病学调查及生存预后相关性分析 [D]; 解放军总医院(北京301医院)&军医进修学院, 2016.